Loading clinical trials...

Personalized B-fructan Diet in Inflammatory Bowel Disease Patients | Clinical Trials | Clareo Health

RECRUITINGNA

Personalized B-fructan Diet in Inflammatory Bowel Disease Patients

The Fibre Study: RCT of Personalized Fibre Diet in IBD

NCT05615779•University of Manitoba

Summary

This study aims to examine patient tolerability of personalized dietary fibre consumption recommendations (high-pectin diet versus high-B-fructan diet based on personalized responses), provided by an IBD dietician, based on our novel translational research findings.

Eligibility

Age

6 - 39 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Children (age 6-17) or young adults (age 18-39).
•Known or suspected UC or IBDU \[there will be 2 control group: non-IBD (undergoing colonoscopy but found not to have IBD; and healthy (no GI symptoms, so not required to have colonoscopy; could be family members)\]
•For UC: Remission-mild-moderate disease: Mayo score \<10
•Clinical indication for sedated colonoscopy
•Disease location: E2-E4
•Stable treatment (not on steroids; biologics or immunomodulator not changed in last month)
•High likelihood that patients will be able to collect all samples and provide all data

Exclusion Criteria

•Use of antibiotics for a week or more over the last 3 months
•Use of probiotics or prebiotics at pharmacological doses (adding fibre sources to food or probiotics in yogurt, for example, are allowed)
•History of abdominal surgery, including appendectomy
•Documented enteric infection during the 3 months prior to endoscopy
•Presence of non-IBD bowel conditions (e.g., celiac), anatomical or mucosal abnormalities, motility disorder
•Presence of a systemic disease requiring treatment (cancer, ischemic heart disease, kidney failure, etc)
•Proctitis (E1)
•Systemic steroids (above 10 mg/day of Prednisone)
•Topical therapy within 1 week of endoscopy
•Recent change in IBD treatment (started biologics or IM over the last month)
+2 more criteria

Locations (2)

University of Alberta Hospital

Edmonton, Alberta, Canada

Health Sciences Centre Hospital

Winnipeg, Manitoba, Canada

Key Dates

Start Date

August 1, 2023

Primary Completion Date

December 1, 2025

Completion Date

December 1, 2025

Last Updated

April 6, 2025

Enrollment

600

ESTIMATED participants

Conditions

Inflammatory Bowel DiseasesUlcerative Colitis

Interventions

Placebo Comparator: Randomized pectin diet

OTHER

Randomized B-fructan diet

OTHER

Personalized pectin diet

OTHER

Personalized B-fructan diet

OTHER

Contacts

Heather Armstrong, MSc, PhD

CONTACT

2047893815 heather.armstrong@umanitoba.ca

Eytan Wine, MD, PhD

CONTACT

wine@umanitoba.ca

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

NCT06226883

Inflammatory Bowel DiseasesCrohn's Disease

View study

RECRUITING

Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis

NCT07271069

Ulcerative Colitis (UC)

View study

RECRUITINGPHASE2

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 6, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Personalized B-fructan Diet in Inflammatory Bowel Disease Patients

Inclusion Criteria

Exclusion Criteria

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis

A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)